Loading stock analysis…
Evidence Synthesis
Last synthesized: 20 Oct 2026, 08:05
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence velocity
Rate-of-change signals for this ticker unlock with Pro — or view flagship demos TCS / RELIANCE.
Evidence Synthesis
GlaxoSmithKline India (GLPL) closed at 32 INR, a decline of 0.013 INR, after a strong quarterly performance with its gross margin accelerating to 64.04%, up from 29.13%.
The company's marginal operating leverage also accelerated to , up from 13.2%.
In terms of trading volume, the company's shares moved from 42,822 to 6,000, a decline of 13,822 shares.
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 64.04 % | 29.13 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 29.13 % | 13.2 | ▲ |
| PRICE_CHANGE_PERCENT | -1.478 % | — | - |
| DAILY_VOLUME | 6,000 shares | 42,822 | ▼ |
| CLOSE_PRICE | 32 INR | 32.48 | ▼ |
Cite this
Source: Samhati evidence synthesis for GLPL (2026-10-20). Observation: GlaxoSmithKline India (GLPL) closed at 32 INR, a decline of 0.013 INR, after a strong quarterly performance with its gross margin accelerating to 64.04%, up from 29.13%. Evidence quality: medium. Not investment advice — no buy, sell, or hold recommendation. Full narrative (Pro): https://samhati.ai/pricing Page: https://samhati.ai/stock/glpl
Filing step-changes